Do We Have to Perform a Renal Biopsy? Clinical Dilemmas in a Case with Nephrotic Syndrome

Tetsu Akimoto, Naoko Otani, Eri Takeshima, Osamu Saito, Eiji Kusano and Daisuke Nagata
Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan.

ABSTRACT: Renal biopsy is one of the pivotal diagnostic tools used in the field of nephrology. A morphological analysis of the kidney may also be of value for the overall management of patients with diabetic nephropathy. However, the indications for renal biopsy differ considerably among nephrologists, and no global consensus regarding performing this procedure among diabetic patients with various renal manifestations has yet been achieved. In this report, we would like to describe our serendipitous experience with a male type 2 diabetic patient presenting with nephrotic syndrome complicated by concurrent gastric carcinoma. We also discuss several conundrums that arose in the current case, which had an impact on our diagnostic and therapeutic decisions.

KEYWORDS: diabetic nephropathy, nephrotic syndrome, paraneoplastic glomerular injury, membranous nephropathy, renal biopsy

Introduction
Renal biopsy is one of the pivotal diagnostic tools used in the field of nephrology. There are numerous diseases that can cause nephrotic syndrome, nephritic syndrome, and acute kidney injury, which have vastly different prognostic and therapeutic implications, illustrating the importance of histopathological examinations in the differential diagnosis. However, the indications for renal biopsy differ considerably among nephrologists, and a global consensus regarding performing this procedure is lacking. In this report, we describe our serendipitous experience with a male type 2 diabetic patient presenting with nephrotic syndrome complicated by concurrent gastric carcinoma. We also discuss several conundrums that arose in the current case, which had an impact on our diagnostic and therapeutic decisions.

Case Report
A 64-year-old male was referred to our unit with complaints of progressive swelling of his legs and weight gain of approximately 5 kg. Thirteen years before, he was found to have type 2 diabetes. Thereafter, he had received combination treatment with oral voglibose and nateglinide, which had kept his HbA1c levels between 6 and 7%. His serum creatinine (sCr) levels had increased gradually during the last two years. He had noticed the symptoms about three months before the referral, when his level of blood sCr was 1.7 mg/dL. He denied the use of any drugs, and his medical histories included hypertension and hyperlipidemia for more than 10 years.

His physical examination at the referral was unremarkable except for periorbital and leg edema. The laboratory data obtained on admission are summarized in Table 1. Tests for hepatitis B virus surface antigens and antibodies to the hepatitis C virus were negative. Renal sonography showed that the renal dimensions of the right kidney measured 113 × 60 mm, while those of the left kidney measured 115 × 66 mm, and the degree of renal cortex echogenicity was normal. The patient’s urine was 3+ for protein and contained 8.9 g of protein in a 24 hour specimen. His proteinuria selectivity index...
The renal biopsy consisted of three cores of renal parenchyma with 32 glomeruli, almost half of which were globally sclerotic. There were glomeruli with hyalinotic lesions, globally widened mesangial regions, and a number of rounded acellular mesangial nodules; and also interstitial infiltration of lymphocytes, atrophic changes in the tubule structure, interstitial fibrosis, and arteriolar hyalinization were identified (Fig. 2). Immunofluorescence staining failed to demonstrate the linear staining of IgG along the glomerular capillary wall. Instead, the presence of focal deposits of IgM in the depending portions of the areas of hyalinosis was confirmed. Electron microscopy failed to show the presence of electron-dense deposits on the subepithelium of the glomerular basement membrane, which is a suggestive finding of membranous nephropathy.

Based on the renal pathological findings, combined with the patient’s clinical pictures, he was finally diagnosed to have nephrotic syndrome due to diabetic nephropathy, and treatment with olmesartan medoxomil at 20 mg/day, amldopidine besilate at 5 mg/day, and furosemide at 80 mg/day, which had been started after the referral, as well as the oral hypoglycemic agents described above, was continued. Despite the absence of any exacerbation of the blood pressure control, his renal function gradually declined and a periodic hemodialysis program finally commenced 21 months after the renal biopsy.

**Discussion**

Performing a renal biopsy for proteinuric diabetics has usually been considered when the presence of a renal disease other than diabetic nephropathy is suggested by clinical signs, such as rapid deterioration of the renal function, microscopic or macroscopic hematuria, and proteinuria in newly diagnosed diabetics without retinopathy or neuropathy. On the other hand, the association of chronic renal insufficiency, nephrotic syndrome, and diabetes with microangiopathic complications such as retinopathy makes a diagnosis of diabetic nephropathy probable, diminishing the need for a renal biopsy. However, several recent studies have suggested a morphological analysis.

---

Table 1. Laboratory data on admission.

| Parameter                      | Value          | Reference Ranges |
|--------------------------------|----------------|------------------|
| White blood cells              | 9400/µl        | (3900–9800)      |
| Hb                             | 11.3 g/dl      | (13.5–17.6)      |
| Platelet count                 | 25.3 × 10^4/µl | (13.0–36.9)      |
| Fibrinogen                     | 716 mg/dl      | (129–271)        |
| D-dimer                        | 2.2 µg/ml      | (0–1.5)          |
| Blood urea nitrogen            | 31 mg/dl       | (8–20)           |
| Creatinine                     | 1.8 mg/dl      | (0.63–1.03)      |
| Total protein                  | 5.9 g/dl       | (6.9–8.4)        |
| Albumin                        | 2.6 g/dl       | (3.9–5.1)        |
| Sodium                         | 142 mmol/l     | (136–148)        |
| Potassium                      | 5.7 mmol/l     | (3.6–5.0)        |
| Chloride                       | 110 mmol/l     | (96–108)         |
| Calcium                        | 8.8 mg/dl      | (8.8–10.1)       |
| Phosphorus                     | 4.0 mg/dl      | (2.4–4.6)        |
| Aspartate aminotransferase     | 15 IU/l        | (11–30)          |
| Alanine aminotransferase       | 13 IU/l        | (4–30)           |
| C-reactive protein             | 0.24 mg/dl     | (0–0.14)         |
| IgG                            | 856 mg/dl      | (870–1700)       |
| IgA                            | 276 mg/dl      | (110–410)        |
| IgM                            | 94 mg/dl       | (33–160)         |
| CEA                            | 1.0 ng/ml      | (<5)             |
| CA19–9                         | 8 U/ml         | (<37)            |
| FBS                            | 151 mg/dl      | (70–109)         |
| HbA1c                          | 6.70%          | (4.3–5.8)        |

**Note:** The reference ranges for each parameter used at our institute are indicated in the brackets.

**Abbreviations:** Hb, hemoglobin; Ig, immunoglobulin; CEA, carcinoembryonic antigen; CA, carbohydrate antigen; FBS, fasting blood sugar.
Nephrotic syndrome and renal biopsy

of the kidney to be of value for the overall management of patients with diabetic nephropathy, implying the diagnostic potential of such a procedure in the overall assessment for diabetics with various renal manifestations. Considering the clinical picture of our patient at the referral, one might have straightforwardly attributed the nephrotic syndrome to diabetic nephropathy without pathological confirmation, and might even argue that the patient's renal pathological findings were not surprising. However, the clinical significance of the current case should be considered carefully in terms of the fact that the concurrent gastric carcinoma was found before arriving at the conclusion that the nephrotic syndrome was etiologically linked to diabetic glomerular injuries.

Nephrotic syndrome has been a focus of studies as one of the pivotal manifestations of the glomerular damage associated with various kinds of neoplasms, while membranous nephropathy, one of the most common causes of adult nephrotic syndrome worldwide, is the most common paraneoplastic glomerulopathy associated with solid tumors. The main problem is to determine how thorough the search for neoplasia should be in such nephrotic subjects. Experts recommend performing basic routine cancer screening procedures, including chest radiography, an occult blood survey of stool specimens, colonoscopy, and measurements of the carcinoembryonic antigen (CEA) and prostate-specific antigen levels, especially in older patients with newly diagnosed membranous nephropathy without any other obvious causes. In addition, further investigations, such as bronchoscopy, gastroscopy, and CT, may be in order after the first-line assessment. However, although some of these examinations may be carried out in the ordinary clinical setting, the extent of the workup depends on the judgment of the primary physician. On the other hand, the validity of such a policy among the nephrotic patients whose renal pathological diagnoses are lacking or those with glomerulopathy other than membranous nephropathy remains to be established. We believe, however, that there are some subsets of nephrotic patients who would benefit from the screening for malignancies, as described in the current report. Otherwise, we might have overlooked the concurrent gastric carcinoma in the present case if we had simply ascribed the nephrotic syndrome to diabetic nephropathy regardless of the presence or absence of the pathological confirmation and had failed to perform upper gastrointestinal endoscopy, which led us to promptly identify the disease.

Fecal immunochemical tests are recommended as the first-choice modality for colorectal cancer screening in average-risk populations, although the current evidence is insufficient to recommend for or against routine surveys to detect gastric or esophageal carcinoma in patients with characteristics similar to those of our patient, ie, positivity for fecal occult blood with negativity on colonoscopy, based on a population-based colorectal cancer screening program. Nevertheless, it has been shown that performing upper gastrointestinal endoscopy in patients with a positive fecal occult blood test alone is not exceptional, even in the field of gastroenterology. We believe that the flexible application of such procedures should be mandatory in nephrotic subjects with these characteristics.

An alternative concern raised from the current case is the role of a renal histological analysis in cancer patients with various renal manifestations, including nephrotic syndrome. In patients with carcinomas that are incurable at the moment of diagnosis, a renal biopsy may not be indicated. Although the relationship between malignancies and nephrotic glomerulopathies is somewhat difficult to prove, it may be suggested by clinical characteristics, such as a close temporal link and parallel evolution, including improvement, resolution, and relapse. Moreover, we should bear in mind that the time to remission of nephrotic syndrome after successful treatment of a malignancy can often be months to years. Nevertheless, the persistence of nephrotic syndrome with a progression
of chronic renal failure in the current patient obliged us to perform a histological survey in view of the possibility of finding a potentially reversible glomerular lesion. One may argue that pathological assessment of the kidney is not warranted in the milieu of chronic renal insufficiency; however, there was a clinical benefit to performing a renal biopsy in the present patient, because it led us to conclude that the presence of a latent relationship between nephrotic syndrome and gastric malignancy was unlikely, and that our patient was incidentally complicated with gastric carcinoma. In the current case, we faced, as do most physicians at various times, diagnostic dilemmas, not only as to whether to perform a renal biopsy but also with respect to how long it is possible to wait to perform a renal biopsy despite progressive deterioration of the patient’s renal function. Obviously, further experience with similar cases is required to resolve such conundrums. The establishment of an optimal management strategy for diabetic patients with both malignancies and various renal manifestations is therefore a matter requiring continuous and careful attention.

**Author Contributions**

TA drafted the manuscript. NO, ET, and OS made contributions to the acquisition of the clinical data. EK and DN provided a detailed review of the contents and structure of the manuscript, resulting in significant changes to the original document. All authors have read and approved the final manuscript.

**REFERENCES**

1. Jennette JC, Olson JL, Schwartz MM, Silva FG. Primer on the pathologic diagnosis of renal disease. In: Jennette JC, Olson JL, Schwartz MM, Silvia FG, eds. *Heptinstall’s Pathology of the Kidney*. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007:97–123.

2. Fuiano G, Mazza G, Comi N, et al. Current indications for renal biopsy: a questionnaire-based survey. *Am J Kidney Dis*. 2000;35(3):448–57.

3. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon; November 30 to December 1, 2002. *Gastrointest Endosc*. 2003;58(6 suppl):S5–43.

4. Akimoto T, Otake T, Tanaka A, et al. Steroid treatment in patients with membranous nephropathy and hepatitis B virus surface antigenemia: a report of two cases. *Clin Exp Nephrol*. 2011;15(2):189–93.

5. Akimoto T, Ito C, Saito O, et al. Microscopic hematuria and diabetic glomerulosclerosis—clinicopathological analysis of type 2 diabetic patients associated with overt proteinuria. *Nephron Clin Pract*. 2008;109(3):e119–26.

6. Otani N, Akimoto T, Yamura W, et al. Is there a link between diabetic glomerular injury and crescent formation? A case report and literature review. *Diagn Pathol*. 2012;7:46.

7. Sugase T, Akimoto T, Iwazu Y, et al. Minimal change nephrotic syndrome complicated with malignant ascites in a patient with type 2 diabetes. *Intern Med*. 2012;51(14):1885–8.

8. Tone A, Shikata K, Matsuda M, et al. Clinical features of non-diabetic renal diseases in patients with type 2 diabetes. *Diabetes Res Clin Pract*. 2005;69(3):237–42.

9. Sharma SG, Bombac AB, Radhakrishnan J, et al. The modern spectrum of renal biopsy findings in patients with diabetes. *Clin J Am Soc Nephrol*. 2013;8(10):1718–24.

10. Caramori ML, Parks A, Mauer M. Renal lesions predict progression of diabetic nephropathy in type 1 diabetes. *J Am Soc Nephrol*. 2013;24(7):1175–81.

11. Jefferson JA, Couger WG. Therapy of membranous nephropathy associated with malignancy and secondary causes. *Semin Nephrol*. 2003;23(4):400–5.

12. Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. *Kidney Int*. 1999;56(1):355–77.

13. Bacchetta J, Juillard L., Cochat P, Droz JP. Paraneoplastic glomerular diseases and malignancies. *Crit Rev Oncol Hematol*. 2009;70(1):39–58.

14. Haas CL, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976–9 and 1995–7. *Am J Kidney Dis*. 1997;30(5):621–31.

15. Ito C, Akimoto T, Nakazawa E, et al. A case of cervical cancer-related membranous nephropathy: a report of two cases. *Clin Exp Nephrol*. 2002;6(3):237–42.

16. Parra-Blanco A, Gimeno-García AZ, Quintero E, et al. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. *J Gastroenterol*. 2010;45(7):703–12.

17. Allard J, Cosby R, Del Giudice ME, Irvine EJ, Morgan D, Tinmouth J. Gastroscopy following a positive faecal occult blood test and negative colonoscopy: systematic review and guideline. *Can J Gastroenterol*. 2010;24(2):113–20.

18. Kim JJ, Han A, Yan AW, Cao D, Laine L. Gastroenterologists’ practice patterns for positive faecal occult blood test. *J Clin Gastroenterol*. 2014;48(2):119–26.

19. Pai P, Bone JM, McDicken I, Bell GM. Solid tumor and glomerulopathy. *QJM*. 1996;89(5):361–7.

20. Madario MP. Renal biopsy. *Kidney Int*. 1990;38(3):529–43.